NovoCure saw the highest growth of 2.44% in patent filings and 1.29% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.44% and grants by 1.29%. GlobalData’s DataBook provides a comprehensive analysis of NovoCure‘s patent filings and grants. Buy the databook here.
NovoCure has been focused on protecting inventions in United States(US) with 41 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 20% grants. The United States(US), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and South Korea(KR) patent Office are among the top ten patent offices where NovoCure is filings its patents. Among the top granted patent authorities, NovoCure has 40% of its grants in European Patent Office(EPO), 33% in Taiwan(TW) and 20% in United States(US).
Boston Scientific and JPMorgan Chase & Co could be the strongest competitors for NovoCure
Patents related to healthtech and nanomedicine lead NovoCure's portfolio
NovoCure has the highest number of patents in healthtech followed by, nanomedicine and remote patient monitoring. For healthtech, nearly 29% of patents were filed and 58% of patents were granted in Q2 2024.
Image management related patents lead NovoCure portfolio followed by diagnostic imaging, and glioblastoma multiforme (gbm)
NovoCure has highest number of patents in image management followed by diagnostic imaging, glioblastoma multiforme (gbm), kidney cancer (renal cell cancer), and healthcare it. For image management, nearly 11% of patents were filed and 14% of patents were granted in Q2 2024.
For comprehensive analysis of NovoCure's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.